Ebola vaccine booster study aims to strengthen protection for frontline workers
NCT ID NCT02788227
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a booster dose of the Ebola vaccine (V920) could improve and extend immune protection in 248 healthy adults at risk of Ebola exposure through their jobs. Participants received the primary vaccine and were randomly assigned 18 months later to get a booster or not. Researchers measured antibody levels over 36 months to see if the booster helped.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ebola vaccine (rVSV∆G-ZEBOV-GP, V920)
What this could lead to
If successful, this could show that a booster shot strengthens and prolongs protection against Ebola for healthcare and lab workers.
What could go wrong
This is a mid-stage study with only 248 participants, so results may not apply to everyone. The vaccine's long-term effectiveness is still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Health Canada, 539 John Buhler Research Center
Winnipeg, Manitoba, R3E 3P4, Canada
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
The Hope Clinic of the Emory Vaccine Center, Emory University
Decatur, Georgia, 30030, United States